CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue	[1]	$ 647,145	$ 469,136	$ 1,286,798	$ 896,826
Expenses
Cost of revenue	[1]	540,302	351,938	1,075,849	662,413
Selling, general and administrative expenses	[1]	69,185	90,389	148,289	180,115
Depreciation and amortization expenses		29,870	32,134	59,373	61,409
Right-of-use assets impairment		0	24,065	0	24,065
Change in fair value of contingent consideration		0	(7,822)	8,908	747
Total operating expenses		639,357	490,704	1,292,419	928,749
Operating income (loss)		7,788	(21,568)	(5,621)	(31,923)
Interest income		1,370	604	3,920	1,664
Interest expense		(5,995)	(14,458)	(11,992)	(27,353)
Gain (loss) from equity method investees		(1,700)	155	(1,394)	578
Change in tax receivables agreement liability		0	0	(173)	(66,184)
Other income (expense), net		(105)	(26)	(97)	(246)
Income (loss) before income taxes		1,358	(35,293)	(15,357)	(123,464)
Provision for (benefit from) income taxes		(238)	(970)	327	(69,159)
Income (loss) before preferred dividends and accretion of Series A Preferred Stock		1,596	(34,323)	(15,684)	(54,305)
Dividends and accretion of Series A Preferred Stock		(7,979)	(7,088)	(15,924)	(13,364)
Net loss attributable to common shareholders of Evolent Health, Inc. - Basic		(6,383)	(41,411)	(31,608)	(67,669)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted		$ (6,383)	$ (41,411)	$ (31,608)	$ (67,669)
Basic and diluted
Basic (in dollars per share)		$ (0.06)	$ (0.37)	$ (0.28)	$ (0.62)
Diluted (in dollars per share)		$ (0.06)	$ (0.37)	$ (0.28)	$ (0.62)
Weighted-average common shares outstanding
Basic (in shares)		114,688	111,278	114,415	109,540
Diluted (in shares)		114,688	111,278	114,415	109,540
Comprehensive loss
Net loss attributable to common shareholders of Evolent Health, Inc.		$ (6,383)	$ (41,411)	$ (31,608)	$ (67,669)
Other comprehensive loss, net of taxes, related to:
Foreign currency translation adjustment		(47)	8	(98)	64
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.		$ (6,430)	$ (41,403)	$ (31,706)	$ (67,605)

[1] See Note 18 for amounts attributable to unconsolidated related parties included in these line items.